Eton Pharmaceuticals, Inc. (ETON) |
| 30.45 -1.41 (-4.43%) 05-29 16:00 |
| Open: | 31.705 |
| High: | 31.955 |
| Low: | 30.08 |
| Volume: | 369,698 |
| Market Cap: | 834(M) |
| PE Ratio: | -507.5 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 41.56 |
| Resistance 1: | 35.58 |
| Pivot price: | 31.58 |
| Support 1: | 27.50 |
| Support 2: | 22.50 |
| 52w High: | 35.66 |
| 52w Low: | 13.09 |
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
| EPS | -0.060 |
| Book Value | 0.970 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.924 |
| Profit Margin (%) | -1.70 |
| Operating Margin (%) | 9.95 |
| Return on Assets (ttm) | 5.3 |
| Return on Equity (ttm) | -5.4 |
Fri, 29 May 2026
Eton Pharmaceuticals CEO Sean Brynjelsen sells $3.83 million in stock - Investing.com
Fri, 29 May 2026
Eton Pharmaceuticals Inc (ETON) Shares Fall 4.3% -- What GF Scor - GuruFocus
Fri, 29 May 2026
(ETON) Volatility Zones as Tactical Triggers - Stock Traders Daily
Fri, 29 May 2026
Eton Pharmaceuticals (ETON) CEO reports open-market sale of 120,000 shares - Stock Titan
Thu, 28 May 2026
120,000 ETON shares proposed for sale by affiliate (ETON) - Stock Titan
Thu, 28 May 2026
Eton Pharmaceuticals, Inc. $ETON Shares Sold by UBS Group AG - MarketBeat
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |